Podcasts about Journal club

Send us a textNesta edição quinzenal do Podcast A Incubadora, as apresentadoras Mariana e Marôla trazem informação acessível, atualizada e em português para profissionais de neonatologia, com a análise crítica de quatro artigos recentes e relevantes para a prática clínica e a pesquisa.No Journal Club 39, discutimos:1. Quantitative lung ultrasound to guide surfactant retreatment in preterm neonates born at ≤30 weeks' gestation – estudo multicêntrico retrospectivo que avalia o uso da ultrassonografia pulmonar quantitativa para orientar a necessidade de nova dose de surfactante. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25)00309-3/fulltext 2. Unbound bilirubin and risk of severe neurodevelopmental impairment in extremely low birthweight newborns– investigação sobre a associação entre bilirrubina não conjugada e risco de comprometimento grave do neurodesenvolvimento em recém-nascidos com peso extremamente baixo. https://pmc.ncbi.nlm.nih.gov/articles/PMC12284093/3. Bridging healthcare gaps: a scoping review on the role of artificial intelligence, deep learning, and large language models in alleviating problems in medical deserts – revisão que explora como a inteligência artificial e modelos de linguagem podem ajudar a reduzir desigualdades no acesso à saúde em áreas carentes. https://academic.oup.com/pmj/article-abstract/101/1191/4/7775387?redirectedFrom=fulltext4. Fenton Third-Generation Growth Charts of Preterm Infants Without Abnormal Fetal Growth: A Systematic Review and Meta-Analysis – revisão sistemática e meta-análise sobre as curvas de crescimento de terceira geração de Fenton para prematuros sem crescimento fetal anormal. https://onlinelibrary.wiley.com/doi/10.1111/ppe.70035Aproveita mais esse episódio do Journal Club, que conecta evidências científicas ao cuidado cotidiano na neonatologia. Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Featuring perspectives from Dr Benjamin Levy, including the following topics: Introduction: The Boards (0:00) Immune Checkpoint Inhibition for Localized Non-Small Cell Lung Cancer (NSCLC) (11:43) Immunotherapy for Metastatic NSCLC (24:41) Antibody-Drug Conjugates (33:46) Novel Bispecific Antibodies (42:08) Journal Club with Dr Levy (51:28) CME information and select publications

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, James Higgins, MD, discuss the following articles from the August 2025 issue: “Toe Transfers Outperform Replantation after Digit Amputations: Outcomes of 126 Toe Transfers” by Lo and Wei. Read the article for FREE: https://bit.ly/126ToeTransfers Special guest, James Higgins, MD is the Chief of The Curtis National Hand Center at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his plastic surgery residency at the University of Rochester, followed by hand fellowship at the Curtis National Hand Center. Among his many accomplishments he was a prior ASRM Godina fellow, ASSH Sterling Bunnell Traveling Fellow, and he currently serves as the vice president of the ASRM Council. He is widely published in hand surgery and upper extremity microsurgery and is a pioneer in upper extremity vascularized bone reconstruction.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCAug25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Podcast Summary This episode of the Pain Exam Podcast, hosted by Dr. David Rosenblum, discusses an interesting article about Ketorolac injections for musculoskeletal conditions. The podcast covers: Ketorolac is an NSAID that provides analgesic and anti-inflammatory effects through inhibition of prostaglandin synthesis Multiple studies comparing Ketorolac injections to corticosteroids and hyaluronic acid for various conditions Research shows Ketorolac injections are equally effective as corticosteroids for subacromial conditions, adhesive capsulitis, carpal-metacarpal joint issues, and hip/knee osteoarthritis Ketorolac may be a safer alternative to steroids for certain patients, though it has its own contraindications for those with renal, gastrointestinal, or cardiovascular disease Dr. Rosenblum considers the potential of using Ketorolac injections directly at pain sites rather than intramuscularly Upcoming Courses and Conferences Ultrasound courses in New York and Costa Rica (check unwrappedpain.org) Private ultrasound sessions available Dr. Rosenblum will be speaking at Pain Week about ultrasound in pain practice and PRP Presenting at a primary care conference in London Teaching ultrasound at ISPN LAPSES conference in Chile (Dr. Rosenblum won't attend this year) Ketorolac Injections: An Effective Alternative for Musculoskeletal Pain Management Musculoskeletal conditions such as bursitis, adhesive capsulitis, and osteoarthritis affect millions and often require injectable therapies to reduce pain and inflammation. Traditionally, corticosteroid injections have been the mainstay treatment. However, concerns over side effects like tendon rupture, cartilage damage, and systemic hyperglycemia have prompted exploration of alternatives. A recent narrative review by Kiel et al. (2024) highlights ketorolac—a parenteral nonsteroidal anti-inflammatory drug (NSAID)—as a promising substitute for corticosteroids in musculoskeletal injections. Warning: OFF Label use of Ketorolac discussed. Please consult your physician. See full article  for details. Subacromial Ketorolac Injections for Shoulder Pain Subacromial bursitis and impingement syndrome are common causes of shoulder pain and disability. Several randomized controlled trials have shown that subacromial ketorolac injections provide pain relief and functional improvement comparable to corticosteroids: Goyal et al. demonstrated significant reductions in pain scores after subacromial injection of 60 mg ketorolac versus 40 mg methylprednisolone, with no difference in outcomes between groups. Taheri et al. found similar short-term pain relief at 1 and 3 months with either ketorolac or corticosteroid subacromial injections. Kim et al. reported equivalent clinical improvement in rotator cuff syndrome patients receiving ketorolac or triamcinolone injections. Min et al. noted ketorolac led to better forward flexion and patient satisfaction at 4 weeks compared to corticosteroids. These studies support ketorolac as an effective agent for subacromial injection, offering an alternative for patients where corticosteroid use is limited. Intra-articular Ketorolac Injections for Adhesive Capsulitis and Osteoarthritis Adhesive capsulitis (frozen shoulder) and osteoarthritis of the hip, knee, and carpometacarpal joint are often treated with intra-articular corticosteroids. Ketorolac injections have shown comparable efficacy in these conditions: Akhtar et al. found intra-articular ketorolac significantly reduced shoulder pain at 4 weeks in adhesive capsulitis compared to hyaluronic acid. Ahn et al. reported similar pain relief between intra-articular ketorolac and corticosteroid injections in adhesive capsulitis, with ketorolac providing superior shoulder mobility at 3 and 6 months. Koh et al. showed that adding ketorolac to hyaluronic acid injections in carpometacarpal osteoarthritis resulted in faster onset of pain relief compared to hyaluronic acid alone. Park et al. observed equivalent functional improvements with intra-articular ketorolac or corticosteroids in hip osteoarthritis. Jurgensmeier et al. demonstrated similar symptom improvement at 1 and 3 months post-injection for ketorolac and triamcinolone in hip and knee osteoarthritis. Xu et al. and Bellamy et al. confirmed ketorolac's comparable pain relief and functional benefits to corticosteroids for knee osteoarthritis, with ketorolac being more cost-effective. Lee et al. noted quicker pain reduction with intra-articular ketorolac combined with hyaluronic acid versus hyaluronic acid alone in knee osteoarthritis. aSafety and Pharmacologic Considerations Ketorolac's anti-inflammatory action stems from cyclooxygenase inhibition, reducing prostaglandin synthesis. Its half-life is approximately 5.2–5.6 hours, and it is metabolized in the liver. Unlike corticosteroids, ketorolac avoids systemic hyperglycemia and cartilage damage risks. Animal and in vitro studies suggest ketorolac may protect cartilage by inhibiting inflammatory cytokines. While gastrointestinal, renal, and cardiovascular risks associated with NSAIDs remain considerations, localized intra-articular and subacromial ketorolac injections may limit systemic exposure and adverse effects. Mild, transient post-injection pain has been reported but resolves without intervention. Conclusion Ketorolac injections, administered intra-articularly or subacromially, are a safe, effective, and economical alternative to corticosteroids for managing common musculoskeletal conditions. Their comparable efficacy in reducing pain and improving function, combined with a more favorable side effect profile, makes ketorolac an appealing option for clinicians and patients alike. Further research is warranted to fully elucidate long-term safety and optimal dosing strategies. FAQS Ketorolac Injections for Musculoskeletal Conditions: Frequently Asked Questions Musculoskeletal pain from conditions like bursitis, adhesive capsulitis, and osteoarthritis often requires injectable treatments. Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is emerging as a promising alternative to corticosteroids. Below are common questions and answers based on a recent narrative review by Kiel et al. (2024). 1. What is ketorolac and how does it work? Ketorolac is a parenteral NSAID that reduces pain and inflammation by inhibiting cyclooxygenase enzymes, which decreases prostaglandin synthesis. It can be administered orally, intramuscularly, intravenously, or by injection directly into joints or around bursae. 2. How effective is ketorolac for musculoskeletal conditions? Studies show ketorolac injections provide significant pain relief and functional improvement comparable to corticosteroids in conditions like: Subacromial bursitis and shoulder impingement (subacromial injections) Adhesive capsulitis (frozen shoulder) (intra-articular injections) Osteoarthritis of the hip, knee, and thumb carpometacarpal joint (intra-articular injections) 3. What evidence supports subacromial ketorolac injections? Randomized controlled trials found: Goyal et al. and Taheri et al. reported similar pain reduction and functional outcomes between ketorolac and corticosteroids for subacromial injections. Kim et al. and Min et al. observed comparable or better patient satisfaction and shoulder mobility with ketorolac versus corticosteroids. 4. How does intra-articular ketorolac compare to corticosteroids for adhesive capsulitis? Akhtar et al. showed ketorolac reduced shoulder pain more than hyaluronic acid. Ahn et al. found ketorolac and corticosteroids equally effective for pain relief, with ketorolac providing better shoulder mobility at 3 and 6 months. 5. What about ketorolac for osteoarthritis? Ketorolac combined with hyaluronic acid provided faster pain relief than hyaluronic acid alone in thumb carpometacarpal joint osteoarthritis (Koh et al.). Intra-articular ketorolac had similar efficacy to corticosteroids in hip (Park et al., Jurgensmeier et al.) and knee osteoarthritis (Bellamy et al., Xu et al.). Ketorolac injections were more cost-effective compared to corticosteroids (Bellamy et al.). 6. Are ketorolac injections safe? Ketorolac's side effects are similar to other NSAIDs, mainly involving gastrointestinal, renal, and cardiovascular risks. However, localized intra-articular and subacromial injections may reduce systemic exposure. Animal studies suggest ketorolac does not harm cartilage and may protect against inflammatory damage. Mild, transient local pain post-injection is possible but usually resolves without treatment. 7. What are the limitations of ketorolac use? Ketorolac is not suitable for patients with: Renal impairment Gastrointestinal ulcers or bleeding risk Cardiovascular disease or hypertension NSAID hypersensitivity, especially in asthma or chronic urticaria patients Clinicians should assess individual risks before choosing ketorolac injections. 8. How does ketorolac's pharmacokinetics affect its use? Ketorolac has a plasma half-life of about 5.2 to 5.6 hours and is metabolized in the liver. Pharmacokinetics for subcutaneous or intra-articular administration are less defined but systemic absorption occurs. Its relatively short half-life supports repeated dosing if needed. 9. Why consider ketorolac over corticosteroids? Ketorolac avoids corticosteroid-associated risks such as tendon rupture, cartilage damage, and steroid-induced hyperglycemia. It is also more cost-effective, making it a favorable option for patients and healthcare systems. 10. What further research is needed? More large-scale, long-term studies are needed to fully understand ketorolac's intra-articular effects, optimal dosing, and safety profile compared to corticosteroids and other treatments. Summary: Ketorolac injections, whether intra-articular or subacromial, offer a safe, effective, and economical alternative to corticosteroids for managing various musculoskeletal conditions. This makes ketorolac an important option in pain management and inflammation control.     Reference: Kiel J, Applewhite AI, Bertasi TGO, Bertasi RAO, Seemann LL, Costa LMC, Helmi H, Pujalte GGA. Ketorolac Injections for Musculoskeletal Conditions: A Narrative Review. Clinical Medicine & Research. 2024;22(1):19-27. DOI: https://doi.org/10.3121/cmr.2024.1847 Disclaimer: This Podcast, website and any content from NRAP Academy (PMRexam.com) otherwise known as Qbazaar.com, LLC is  for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. Professionals should conduct their own fact finding, research, and due diligence to come to their own conclusions for treating patients. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.    

Podcast Summary This episode of the Pain Exam Podcast, hosted by Dr. David Rosenblum, discusses an interesting article about Ketorolac injections for musculoskeletal conditions. The podcast covers: Ketorolac is an NSAID that provides analgesic and anti-inflammatory effects through inhibition of prostaglandin synthesis Multiple studies comparing Ketorolac injections to corticosteroids and hyaluronic acid for various conditions Research shows Ketorolac injections are equally effective as corticosteroids for subacromial conditions, adhesive capsulitis, carpal-metacarpal joint issues, and hip/knee osteoarthritis Ketorolac may be a safer alternative to steroids for certain patients, though it has its own contraindications for those with renal, gastrointestinal, or cardiovascular disease Dr. Rosenblum considers the potential of using Ketorolac injections directly at pain sites rather than intramuscularly Upcoming Courses and Conferences Ultrasound courses in New York and Costa Rica (check unwrappedpain.org) Private ultrasound sessions available Dr. Rosenblum will be speaking at Pain Week about ultrasound in pain practice and PRP Presenting at a primary care conference in London Teaching ultrasound at ISPN LAPS  conference in Chile (Dr. Rosenblum won't attend this year) Ketorolac Injections: An Effective Alternative for Musculoskeletal Pain Management Musculoskeletal conditions such as bursitis, adhesive capsulitis, and osteoarthritis affect millions and often require injectable therapies to reduce pain and inflammation. Traditionally, corticosteroid injections have been the mainstay treatment. However, concerns over side effects like tendon rupture, cartilage damage, and systemic hyperglycemia have prompted exploration of alternatives. A recent narrative review by Kiel et al. (2024) highlights ketorolac—a parenteral nonsteroidal anti-inflammatory drug (NSAID)—as a promising substitute for corticosteroids in musculoskeletal injections. Warning: OFF Label use of Ketorolac discussed. Please consult your physician. See full article  for details. Subacromial Ketorolac Injections for Shoulder Pain Subacromial bursitis and impingement syndrome are common causes of shoulder pain and disability. Several randomized controlled trials have shown that subacromial ketorolac injections provide pain relief and functional improvement comparable to corticosteroids: Goyal et al. demonstrated significant reductions in pain scores after subacromial injection of 60 mg ketorolac versus 40 mg methylprednisolone, with no difference in outcomes between groups. Taheri et al. found similar short-term pain relief at 1 and 3 months with either ketorolac or corticosteroid subacromial injections. Kim et al. reported equivalent clinical improvement in rotator cuff syndrome patients receiving ketorolac or triamcinolone injections. Min et al. noted ketorolac led to better forward flexion and patient satisfaction at 4 weeks compared to corticosteroids. These studies support ketorolac as an effective agent for subacromial injection, offering an alternative for patients where corticosteroid use is limited. Intra-articular Ketorolac Injections for Adhesive Capsulitis and Osteoarthritis Adhesive capsulitis (frozen shoulder) and osteoarthritis of the hip, knee, and carpometacarpal joint are often treated with intra-articular corticosteroids. Ketorolac injections have shown comparable efficacy in these conditions: Akhtar et al. found intra-articular ketorolac significantly reduced shoulder pain at 4 weeks in adhesive capsulitis compared to hyaluronic acid. Ahn et al. reported similar pain relief between intra-articular ketorolac and corticosteroid injections in adhesive capsulitis, with ketorolac providing superior shoulder mobility at 3 and 6 months. Koh et al. showed that adding ketorolac to hyaluronic acid injections in carpometacarpal osteoarthritis resulted in faster onset of pain relief compared to hyaluronic acid alone. Park et al. observed equivalent functional improvements with intra-articular ketorolac or corticosteroids in hip osteoarthritis. Jurgensmeier et al. demonstrated similar symptom improvement at 1 and 3 months post-injection for ketorolac and triamcinolone in hip and knee osteoarthritis. Xu et al. and Bellamy et al. confirmed ketorolac's comparable pain relief and functional benefits to corticosteroids for knee osteoarthritis, with ketorolac being more cost-effective. Lee et al. noted quicker pain reduction with intra-articular ketorolac combined with hyaluronic acid versus hyaluronic acid alone in knee osteoarthritis. aSafety and Pharmacologic Considerations Ketorolac's anti-inflammatory action stems from cyclooxygenase inhibition, reducing prostaglandin synthesis. Its half-life is approximately 5.2–5.6 hours, and it is metabolized in the liver. Unlike corticosteroids, ketorolac avoids systemic hyperglycemia and cartilage damage risks. Animal and in vitro studies suggest ketorolac may protect cartilage by inhibiting inflammatory cytokines. While gastrointestinal, renal, and cardiovascular risks associated with NSAIDs remain considerations, localized intra-articular and subacromial ketorolac injections may limit systemic exposure and adverse effects. Mild, transient post-injection pain has been reported but resolves without intervention. Conclusion Ketorolac injections, administered intra-articularly or subacromially, are a safe, effective, and economical alternative to corticosteroids for managing common musculoskeletal conditions. Their comparable efficacy in reducing pain and improving function, combined with a more favorable side effect profile, makes ketorolac an appealing option for clinicians and patients alike. Further research is warranted to fully elucidate long-term safety and optimal dosing strategies. FAQS Ketorolac Injections for Musculoskeletal Conditions: Frequently Asked Questions Musculoskeletal pain from conditions like bursitis, adhesive capsulitis, and osteoarthritis often requires injectable treatments. Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is emerging as a promising alternative to corticosteroids. Below are common questions and answers based on a recent narrative review by Kiel et al. (2024). 1. What is ketorolac and how does it work? Ketorolac is a parenteral NSAID that reduces pain and inflammation by inhibiting cyclooxygenase enzymes, which decreases prostaglandin synthesis. It can be administered orally, intramuscularly, intravenously, or by injection directly into joints or around bursae. 2. How effective is ketorolac for musculoskeletal conditions? Studies show ketorolac injections provide significant pain relief and functional improvement comparable to corticosteroids in conditions like: Subacromial bursitis and shoulder impingement (subacromial injections) Adhesive capsulitis (frozen shoulder) (intra-articular injections) Osteoarthritis of the hip, knee, and thumb carpometacarpal joint (intra-articular injections) 3. What evidence supports subacromial ketorolac injections? Randomized controlled trials found: Goyal et al. and Taheri et al. reported similar pain reduction and functional outcomes between ketorolac and corticosteroids for subacromial injections. Kim et al. and Min et al. observed comparable or better patient satisfaction and shoulder mobility with ketorolac versus corticosteroids. 4. How does intra-articular ketorolac compare to corticosteroids for adhesive capsulitis? Akhtar et al. showed ketorolac reduced shoulder pain more than hyaluronic acid. Ahn et al. found ketorolac and corticosteroids equally effective for pain relief, with ketorolac providing better shoulder mobility at 3 and 6 months. 5. What about ketorolac for osteoarthritis? Ketorolac combined with hyaluronic acid provided faster pain relief than hyaluronic acid alone in thumb carpometacarpal joint osteoarthritis (Koh et al.). Intra-articular ketorolac had similar efficacy to corticosteroids in hip (Park et al., Jurgensmeier et al.) and knee osteoarthritis (Bellamy et al., Xu et al.). Ketorolac injections were more cost-effective compared to corticosteroids (Bellamy et al.). 6. Are ketorolac injections safe? Ketorolac's side effects are similar to other NSAIDs, mainly involving gastrointestinal, renal, and cardiovascular risks. However, localized intra-articular and subacromial injections may reduce systemic exposure. Animal studies suggest ketorolac does not harm cartilage and may protect against inflammatory damage. Mild, transient local pain post-injection is possible but usually resolves without treatment. 7. What are the limitations of ketorolac use? Ketorolac is not suitable for patients with: Renal impairment Gastrointestinal ulcers or bleeding risk Cardiovascular disease or hypertension NSAID hypersensitivity, especially in asthma or chronic urticaria patients Clinicians should assess individual risks before choosing ketorolac injections. 8. How does ketorolac's pharmacokinetics affect its use? Ketorolac has a plasma half-life of about 5.2 to 5.6 hours and is metabolized in the liver. Pharmacokinetics for subcutaneous or intra-articular administration are less defined but systemic absorption occurs. Its relatively short half-life supports repeated dosing if needed. 9. Why consider ketorolac over corticosteroids? Ketorolac avoids corticosteroid-associated risks such as tendon rupture, cartilage damage, and steroid-induced hyperglycemia. It is also more cost-effective, making it a favorable option for patients and healthcare systems. 10. What further research is needed? More large-scale, long-term studies are needed to fully understand ketorolac's intra-articular effects, optimal dosing, and safety profile compared to corticosteroids and other treatments. Summary: Ketorolac injections, whether intra-articular or subacromial, offer a safe, effective, and economical alternative to corticosteroids for managing various musculoskeletal conditions. This makes ketorolac an important option in pain management and inflammation control.     Reference: Kiel J, Applewhite AI, Bertasi TGO, Bertasi RAO, Seemann LL, Costa LMC, Helmi H, Pujalte GGA. Ketorolac Injections for Musculoskeletal Conditions: A Narrative Review. Clinical Medicine & Research. 2024;22(1):19-27. DOI: https://doi.org/10.3121/cmr.2024.1847 Disclaimer: This Podcast, website and any content from NRAP Academy (PMRexam.com) otherwise known as Qbazaar.com, LLC is  for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. Professionals should conduct their own fact finding, research, and due diligence to come to their own conclusions for treating patients. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.  

Podcast Summary This episode of the Pain Exam Podcast, hosted by Dr. David Rosenblum, discusses an interesting article about Ketorolac injections for musculoskeletal conditions. The podcast covers: Ketorolac is an NSAID that provides analgesic and anti-inflammatory effects through inhibition of prostaglandin synthesis Multiple studies comparing Ketorolac injections to corticosteroids and hyaluronic acid for various conditions Research shows Ketorolac injections are equally effective as corticosteroids for subacromial conditions, adhesive capsulitis, carpal-metacarpal joint issues, and hip/knee osteoarthritis Ketorolac may be a safer alternative to steroids for certain patients, though it has its own contraindications for those with renal, gastrointestinal, or cardiovascular disease Dr. Rosenblum considers the potential of using Ketorolac injections directly at pain sites rather than intramuscularly Upcoming Courses and Conferences Ultrasound courses in New York and Costa Rica (check unwrappedpain.org) Private ultrasound sessions available Dr. Rosenblum will be speaking at Pain Week about ultrasound in pain practice and PRP Presenting at a primary care conference in London Teaching ultrasound at ISPN LAPSES conference in Chile (Dr. Rosenblum won't attend this year) Ketorolac Injections: An Effective Alternative for Musculoskeletal Pain Management Musculoskeletal conditions such as bursitis, adhesive capsulitis, and osteoarthritis affect millions and often require injectable therapies to reduce pain and inflammation. Traditionally, corticosteroid injections have been the mainstay treatment. However, concerns over side effects like tendon rupture, cartilage damage, and systemic hyperglycemia have prompted exploration of alternatives. A recent narrative review by Kiel et al. (2024) highlights ketorolac—a parenteral nonsteroidal anti-inflammatory drug (NSAID)—as a promising substitute for corticosteroids in musculoskeletal injections. Warning: OFF Label use of Ketorolac discussed. Please consult your physician. See full article  for details. Subacromial Ketorolac Injections for Shoulder Pain Subacromial bursitis and impingement syndrome are common causes of shoulder pain and disability. Several randomized controlled trials have shown that subacromial ketorolac injections provide pain relief and functional improvement comparable to corticosteroids: Goyal et al. demonstrated significant reductions in pain scores after subacromial injection of 60 mg ketorolac versus 40 mg methylprednisolone, with no difference in outcomes between groups. Taheri et al. found similar short-term pain relief at 1 and 3 months with either ketorolac or corticosteroid subacromial injections. Kim et al. reported equivalent clinical improvement in rotator cuff syndrome patients receiving ketorolac or triamcinolone injections. Min et al. noted ketorolac led to better forward flexion and patient satisfaction at 4 weeks compared to corticosteroids. These studies support ketorolac as an effective agent for subacromial injection, offering an alternative for patients where corticosteroid use is limited. Intra-articular Ketorolac Injections for Adhesive Capsulitis and Osteoarthritis Adhesive capsulitis (frozen shoulder) and osteoarthritis of the hip, knee, and carpometacarpal joint are often treated with intra-articular corticosteroids. Ketorolac injections have shown comparable efficacy in these conditions: Akhtar et al. found intra-articular ketorolac significantly reduced shoulder pain at 4 weeks in adhesive capsulitis compared to hyaluronic acid. Ahn et al. reported similar pain relief between intra-articular ketorolac and corticosteroid injections in adhesive capsulitis, with ketorolac providing superior shoulder mobility at 3 and 6 months. Koh et al. showed that adding ketorolac to hyaluronic acid injections in carpometacarpal osteoarthritis resulted in faster onset of pain relief compared to hyaluronic acid alone. Park et al. observed equivalent functional improvements with intra-articular ketorolac or corticosteroids in hip osteoarthritis. Jurgensmeier et al. demonstrated similar symptom improvement at 1 and 3 months post-injection for ketorolac and triamcinolone in hip and knee osteoarthritis. Xu et al. and Bellamy et al. confirmed ketorolac's comparable pain relief and functional benefits to corticosteroids for knee osteoarthritis, with ketorolac being more cost-effective. Lee et al. noted quicker pain reduction with intra-articular ketorolac combined with hyaluronic acid versus hyaluronic acid alone in knee osteoarthritis. aSafety and Pharmacologic Considerations Ketorolac's anti-inflammatory action stems from cyclooxygenase inhibition, reducing prostaglandin synthesis. Its half-life is approximately 5.2–5.6 hours, and it is metabolized in the liver. Unlike corticosteroids, ketorolac avoids systemic hyperglycemia and cartilage damage risks. Animal and in vitro studies suggest ketorolac may protect cartilage by inhibiting inflammatory cytokines. While gastrointestinal, renal, and cardiovascular risks associated with NSAIDs remain considerations, localized intra-articular and subacromial ketorolac injections may limit systemic exposure and adverse effects. Mild, transient post-injection pain has been reported but resolves without intervention. Conclusion Ketorolac injections, administered intra-articularly or subacromially, are a safe, effective, and economical alternative to corticosteroids for managing common musculoskeletal conditions. Their comparable efficacy in reducing pain and improving function, combined with a more favorable side effect profile, makes ketorolac an appealing option for clinicians and patients alike. Further research is warranted to fully elucidate long-term safety and optimal dosing strategies. FAQS Ketorolac Injections for Musculoskeletal Conditions: Frequently Asked Questions Musculoskeletal pain from conditions like bursitis, adhesive capsulitis, and osteoarthritis often requires injectable treatments. Ketorolac, a nonsteroidal anti-inflammatory drug (NSAID), is emerging as a promising alternative to corticosteroids. Below are common questions and answers based on a recent narrative review by Kiel et al. (2024). 1. What is ketorolac and how does it work? Ketorolac is a parenteral NSAID that reduces pain and inflammation by inhibiting cyclooxygenase enzymes, which decreases prostaglandin synthesis. It can be administered orally, intramuscularly, intravenously, or by injection directly into joints or around bursae. 2. How effective is ketorolac for musculoskeletal conditions? Studies show ketorolac injections provide significant pain relief and functional improvement comparable to corticosteroids in conditions like: Subacromial bursitis and shoulder impingement (subacromial injections) Adhesive capsulitis (frozen shoulder) (intra-articular injections) Osteoarthritis of the hip, knee, and thumb carpometacarpal joint (intra-articular injections) 3. What evidence supports subacromial ketorolac injections? Randomized controlled trials found: Goyal et al. and Taheri et al. reported similar pain reduction and functional outcomes between ketorolac and corticosteroids for subacromial injections. Kim et al. and Min et al. observed comparable or better patient satisfaction and shoulder mobility with ketorolac versus corticosteroids. 4. How does intra-articular ketorolac compare to corticosteroids for adhesive capsulitis? Akhtar et al. showed ketorolac reduced shoulder pain more than hyaluronic acid. Ahn et al. found ketorolac and corticosteroids equally effective for pain relief, with ketorolac providing better shoulder mobility at 3 and 6 months. 5. What about ketorolac for osteoarthritis? Ketorolac combined with hyaluronic acid provided faster pain relief than hyaluronic acid alone in thumb carpometacarpal joint osteoarthritis (Koh et al.). Intra-articular ketorolac had similar efficacy to corticosteroids in hip (Park et al., Jurgensmeier et al.) and knee osteoarthritis (Bellamy et al., Xu et al.). Ketorolac injections were more cost-effective compared to corticosteroids (Bellamy et al.). 6. Are ketorolac injections safe? Ketorolac's side effects are similar to other NSAIDs, mainly involving gastrointestinal, renal, and cardiovascular risks. However, localized intra-articular and subacromial injections may reduce systemic exposure. Animal studies suggest ketorolac does not harm cartilage and may protect against inflammatory damage. Mild, transient local pain post-injection is possible but usually resolves without treatment. 7. What are the limitations of ketorolac use? Ketorolac is not suitable for patients with: Renal impairment Gastrointestinal ulcers or bleeding risk Cardiovascular disease or hypertension NSAID hypersensitivity, especially in asthma or chronic urticaria patients Clinicians should assess individual risks before choosing ketorolac injections. 8. How does ketorolac's pharmacokinetics affect its use? Ketorolac has a plasma half-life of about 5.2 to 5.6 hours and is metabolized in the liver. Pharmacokinetics for subcutaneous or intra-articular administration are less defined but systemic absorption occurs. Its relatively short half-life supports repeated dosing if needed. 9. Why consider ketorolac over corticosteroids? Ketorolac avoids corticosteroid-associated risks such as tendon rupture, cartilage damage, and steroid-induced hyperglycemia. It is also more cost-effective, making it a favorable option for patients and healthcare systems. 10. What further research is needed? More large-scale, long-term studies are needed to fully understand ketorolac's intra-articular effects, optimal dosing, and safety profile compared to corticosteroids and other treatments. Summary: Ketorolac injections, whether intra-articular or subacromial, offer a safe, effective, and economical alternative to corticosteroids for managing various musculoskeletal conditions. This makes ketorolac an important option in pain management and inflammation control.     Reference: Kiel J, Applewhite AI, Bertasi TGO, Bertasi RAO, Seemann LL, Costa LMC, Helmi H, Pujalte GGA. Ketorolac Injections for Musculoskeletal Conditions: A Narrative Review. Clinical Medicine & Research. 2024;22(1):19-27. DOI: https://doi.org/10.3121/cmr.2024.1847 Disclaimer: This Podcast, website and any content from NRAP Academy (PMRexam.com) otherwise known as Qbazaar.com, LLC is  for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. Professionals should conduct their own fact finding, research, and due diligence to come to their own conclusions for treating patients. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.    

Los artículos que se tratan en el episodio de hoy están listados aquí: Associations of Bronchopulmonary Dysplasia and Infection with School-Age Brain Development in Children Born Preterm.Kim C, Ufkes S, Guo T, Chau V, Synnes A, Grunau RE, Miller SP.J Pediatr. 2025 Jun;281:114524. doi: 10.1016/j.jpeds.2025.114524. Epub 2025 Feb 27. PMID: 40023219.Active Treatment vs Expectant Management of Patent Ductus Arteriosus in Preterm Infants: A Meta-Analysis.Buvaneswarran S, Wong YL, Liang S, Quek SC, Lee J.JAMA Pediatr. 2025 May 27:e251025. doi: 10.1001/jamapediatrics.2025.1025. Online ahead of print.PMID: 40423988 Occurrence and Time of Onset of Intraventricular Hemorrhage in Preterm Neonates: A Systematic Review and Meta-Analysis of Individual Patient Data.Nagy Z, Obeidat M, Máté V, Nagy R, Szántó E, Veres DS, Kói T, Hegyi P, Major GS, Garami M, Gasparics Á, Te Pas AB, Szabó M.JAMA Pediatr. 2025 Feb 1;179(2):145-154. doi: 10.1001/jamapediatrics.2024.5998.PMID: 39786414  Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comSíguenos en nuestras redes:Twitter: @incubadorapodInstagram: @laincubadorapodcast Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers. CME information and select publications here.

People Overtrust AI-Generated Medical Advice despite Low Accuracy - ⁠Link⁠---Nova Android & iOS app MGFamiliar - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Link⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---Subscreva o Podcast MGFamiliar para não perder qualquer um dos nossos episódios. Além disso, considere deixar-nos uma revisão ou um comentário no Apple Podcasts ou no Spotify.---MusicFreedom by Roa   / roa_music1031   Creative Commons — Attribution 3.0 Unported — CC BY 3.0Free Download / Stream: https://www.audiolibrary.com.co/roa-m...Music promoted by Audio Library    • Freedom – Roa (No Copyright Music) 

Featuring an interview with Dr Erika Hamilton, including the following topics: Optimal selection and sequencing of available antibody-drug conjugates for HR-positive metastatic breast cancer (0:00) Bardia A et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01. J Clin Oncol 2025;43(3):285-96. Abstract  Pistilli B et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival from the Phase III TROPION-Breast01 trial. ESMO Virtual Plenary 2025;Abstract VP1-2025. First-line use of sacituzumab govitecan in combination with pembrolizumab for advanced triple-negative breast cancer (8:02) Tolaney SM et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. ASCO 2025;Abstract LBA109. Ongoing trials evaluating datopotamab deruxtecan in earlier lines of therapy (12:06) Dent RA et al. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncol 2023;19(35):2349-59. Abstract McArthur HL et al. TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer. Ther Adv Med Oncol 2025;17:17588359251316176. Abstract Bardia A et al. TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol 2024;16:17588359241248336. Abstract Schmid P et al. TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Ther Adv Med Oncol 2025;17:17588359251327992. Abstract Available data with and ongoing trials of sacituzumab tirumotecan for HR-positive, HER2-negative and triple-negative breast cancer (16:53) Yin Y et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. ASCO 2025;Abstract 1019. Xu B et al. Sacituzumab tirumotecan in patients with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the Phase III Opti-TROP-Breast01 study. ASCO 2024;Abstract 104. Yin Y et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial. Nat Med 2025;31(6):1969-1975. Abstract Garrido-Castro AC et al. SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic HR+/HER2-negative breast cancer. ASCO 2024;Abstract LBA1004. CME information and select publications

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Antihypertensive Medication Timing and Cardiovascular Events and Death The BedMed Randomized Clinical Trial JAMA 2025.  Discussion by: Guest:Susan Kuchera, MDDirector of the Family Medicine Residency ProgramJefferson Health - Abington2. Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. 2025.  Discussion by: Guest:Eden Miller, MDDiabetes and Obesity SpecialistBend, Oregon 3. As-Needed Albuterol–Budesonide in Mild Asthma. The New England Journal of Medicine.  Discussion by: Guest:Dylan Selden, MDResident– Family Medicine Residency Program Jefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

In this episode of Season 6 I am sharing about confidence within your career, small business, work etc. as a women and what might hold us back. You will hear me talk about: why we might struggle to feel confident in our career or next steps how to deepen your confidence in your career A range of journaling prompts to support the self-awareness and exploration   This episode of the Self Care Edit is sponsored by Juno Magazine ~ "a print and digital bi-monthly magazine which promotes a natural approach to family life and inspires and supports parents as they journey through the challenges of parenting." Find out more and get your copy or subscription here ~ https://junomagazine.com/   To see more of Emma, the Journal Club, Journals, Online Courses and Coaching Sessions, resources and workshops head to: Journals - https://www.amazon.co.uk/stores/Ms-Emma-Benyon/author/B0DMM7KKTG Facebook - @emmabenyon.coach Instagram - @emmabenyon.coach Instagram - @journalingwithemma Website - https://emmabenyoncoaching.co.uk/ Email - emma@emmabenyoncoaching.co.uk If you are ready to deepen your journaling practice, find out more about my four week online journaling course ~ https://emmabenyoncoaching.co.uk/journaling-courses/mindfulmomentsjournalingcourse Sign up to the newsletter and get your Wellness Life Check and review your life right now ~ https://dashboard.mailerlite.com/forms/851037/114640934069601722/share

Der Sommer ist in vollem Gange und wir präsentieren Euch die neue Hauptfolge.. Wir sprechen unter anderem mit dem Neurologen Dr. Christian Claudi, der uns das FAST-4D Konzept vorstellt und haben als zweites Thema noch den aktuellen Stand der Wirbelsäulen-Immobilisation. Außerdem gibts wieder einen Journal Club und einen spannenden Lieblingsfehler. Ankündigungen: Ab 15.08.25 findet ihr unser Regionalanästhesie Skript auf unserer […] Der Beitrag Hauptfolge Juli 2025 – Folge 79 erschien zuerst auf pin-up-docs - don't panic.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, James Higgins, MD, discuss the following articles from the August 2025 issue:   “Toe Transfers Outperform Replantation after Digit Amputations: Outcomes of 126 Toe Transfers” by Lo and Wei.   “Improving Patient Transfer Quality: A Retrospective Study on a Transfer Center for a Canadian Upper Extremity Revascularization Program” by Arsenault, Efanov, Lavoie, et al.   “Interfacility Competition and Its Impact on Cost of Carpal Tunnel Release” by Rivedal, Cichocki, Tong, et al.   Special guest, James Higgins, MD is the Chief of The Curtis National Hand Center at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his plastic surgery residency at the University of Rochester, followed by hand fellowship at the Curtis National Hand Center. Among his many accomplishments he was a prior ASRM Godina fellow, ASSH Sterling Bunnell Traveling Fellow, and he currently serves as the vice president of the ASRM Council. He is widely published in hand surgery and upper extremity microsurgery and is a pioneer in upper extremity vascularized bone reconstruction.   READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCAug25Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Send us a textWelcome to The Oncology Journal Club Podcast Series 3Hosted by Professor Craig Underhill, Dr Kate Clarke & Professor Christopher Jackson | Proudly produced by The Oncology NetworkWelcome to Episode 6 of The Oncology Journal Club podcast. This is where we take a famously different approach to oncology research.Has non-operative management finally found its place in treating certain cancers? This episode unpacks compelling new data that might challenge the surgeon's traditional role for some patients with mismatch repair deficient tumours. While rectal cancer patients show remarkable complete response rates to immunotherapy, the story gets more complex across different cancer types – raising fascinating questions about tumour biology, patient selection and the future of organ preservation.We explore the delicate art of discussing immunotherapy outcomes with patients, navigating that narrow path between hope and realism. When treatments occasionally produce dramatic responses but more commonly offer limited benefits, how do oncologists communicate effectively without creating unrealistic expectations? Our hosts share practical strategies for these challenging conversations, emphasising that truly patient-centred care requires ongoing dialogue about prognosis.The oncology research world is evolving too, with updated CONSORT and SPIRIT guidelines transforming how clinical trials are designed and reported. These frameworks now mandate greater transparency, clearer safety reporting and increased patient involvement in study design – potentially leading to more trustworthy and applicable research outcomes.Plus, we examine an intriguing Chinese trial showing remarkable survival benefits from low-dose continuous capecitabine combined with aromatase inhibitors for metastatic breast cancer – a potential game-changer for resource-limited settings.From this year's AACR meeting, we highlight what might be the first change in standard of care for locally advanced head and neck cancer in two decades, along with promising targeted therapies for specific molecular subtypes of lung cancer. Join our expert hosts Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson as they navigate these developments with their trademark blend of critical analysis, clinical wisdom and humour. Subscribe to The Oncology Newsletter to stay informed about the evolving landscape of oncology care and research.For links to the abstracts and bios of our hosts, head to the show notes on oncologynetwork.com.au.The Oncology Podcast - An Australian Oncology Perspective

In this episode of Season 6 I am joined by guest expert Emma Eldershaw, the Self-Belief Coach for Women in Business for an episode all about Self-Belief. You will hear us talk about: what self belief is and how this impacts on us as women why is important we build our self belief  what can we do to have more self belief as women   Find out more about Emma ~ Emma Eldershaw is the Self-Belief Coach for Women in Business and is a certified NLP Master Practitioner and mBIT Coach. Her  journey into coaching has been anything but ordinary, shaped by personal battles and professional experiences that she now uses to help other women overcome their own struggles. She is passionate about helping women in business because she knows how it feels to lack confidence in yourself.  Website - www.theselfbeliefcoach.co.uk Facebook - https://www.facebook.com/share/g/1C4uxMJoFN/ Instagram - https://www.instagram.com/emma_theselfbeliefcoach Special offer for my listeners: Half Price Breakthrough Session £75 (normally £150) with Emma (offer available till 22.08.25) A powerful 90 minute, one to one session where we take a deep dive into what's holding you back and to start moving you forward with long lasting tools and techniques to help you achieve your goals and dreams. To book please contact Emma via her social media channels     This episode of the Self Care Edit is sponsored by Juno Magazine ~ "a print and digital bi-monthly magazine which promotes a natural approach to family life and inspires and supports parents as they journey through the challenges of parenting." Find out more and get your copy or subscription here ~ https://junomagazine.com/   To see more of Emma, the Journal Club, Journals, Online Courses and Coaching Sessions, resources and workshops head to: Journals - https://www.amazon.co.uk/stores/Ms-Emma-Benyon/author/B0DMM7KKTG Facebook - @emmabenyon.coach Instagram - @emmabenyon.coach Instagram - @journalingwithemma Website - https://emmabenyoncoaching.co.uk/ Email - emma@emmabenyoncoaching.co.uk If you are ready to deepen your journaling practice, find out more about my four week online journaling course ~ https://emmabenyoncoaching.co.uk/journaling-courses/mindfulmomentsjournalingcourse Sign up to the newsletter and get your Wellness Life Check and review your life right now ~ https://dashboard.mailerlite.com/forms/851037/114640934069601722/share

Join Dr. Sruti Akella and a distinguished panel, including Dr. Raymond Cho, Dr. Chau Pham, and Dr. Ann Tran, as they delve into key discussions from the May-June issue of OPRS. Topics include innovative management of pediatric eyelid burns, cost analysis of enucleation vs. evisceration surgeries, and optimal surgery timing after teprotumumab for thyroid eye disease. Gain insights into evolving surgical techniques and the role of new treatments, with expert perspectives from major academic centers. If you're an ASOPRS Member, Surgeon or Trainee and are interesting in hosting a podcast episode, please submit your idea by visiting: www.asoprs.memberclicks.net/podcast

Send us a textPerinatal Urinary Tract Dilation: Recommendations on Pre-/Postnatal Imaging, Prophylactic Antibiotics, and Follow-up: Clinical Report.Anthony Herndon CD, Otero HJ, Hains D, Sweeney RM, Lockwood GM; Section on Urology; Section on Nephrology; Section on Radiology; Section on Hospital Medicine.Pediatrics. 2025 Jul 1;156(1):e2025071814. doi: 10.1542/peds.2025-071814.PMID: 40518141 Review.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this week's Journal Club, Ben and Daphna dive into several impactful neonatal studies shaping today's clinical decisions. The discussion opens with the MOCA Trial, exploring whether extending caffeine therapy in moderately preterm infants reduces hospital stays and improves outcomes. Despite reducing apnea episodes, the study highlights that extending caffeine treatment does not reduce time to discharge.Next, the team reviews a randomized trial on late permissive hypercapnia in mechanically ventilated preterm infants, showing that targeting slightly higher CO₂ levels can shorten invasive ventilation time without worsening long-term outcomes.Midway through the episode, we feature an EBNEO commentary with Dr. Kira McNellis on early full enteral nutrition with fortified milk in very preterm infants. She explains why fat-free mass is an important nutritional marker linked to neurodevelopment and why “negative” nutrition studies still matter for clinical practice.Other key papers include cumulative neonatal morbidities predicting long-term neurodevelopment, the long-term academic Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textPatient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease.Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, Silverstein RA, Hille LT, Ogul AN, Robinson-Garvin NA, Small JC, McCague S, Burke SM, Wright CM, Bick S, Indurthi V, Sharma S, Jepperson M, Vakulskas CA, Collingwood M, Keogh K, Jacobi A, Sturgeon M, Brommel C, Schmaljohn E, Kurgan G, Osborne T, Zhang H, Kinney K, Rettig G, Barbosa CJ, Semple SC, Tam YK, Lutz C, George LA, Kleinstiver BP, Liu DR, Ng K, Kassim SH, Giannikopoulos P, Alameh MG, Urnov FD, Ahrens-Nicklas RC.N Engl J Med. 2025 Jun 12;392(22):2235-2243. doi: 10.1056/NEJMoa2504747. Epub 2025 May 15.PMID: 40373211Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textSchool outcomes after HIE: a population-based cohort study.Rees P, Dronavalli M, Carter B, Bajuk B, Burns L, Dickson M, Eastwood J, Hossain S, Lawler K, Lee E, Munasinghe S, Page A, Uebel H, Dicair L, Green C, Gale C, Oei JL.Arch Dis Child Fetal Neonatal Ed. 2025 Jun 8:fetalneonatal-2024-328346. doi: 10.1136/archdischild-2024-328346. Online ahead of print.PMID: 40484626Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textEarly full enteral nutrition with fortified milk in very preterm infants: a randomized clinical trial.Salas AA, Gunawan E, Jeffcoat S, Nguyen K.Am J Clin Nutr. 2025 May;121(5):1117-1123. doi: 10.1016/j.ajcnut.2025.02.019. Epub 2025 Feb 21.PMID: 39986385 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textAssociation of a Count of Inpatient Morbidities with 2-Year Outcomes among Infants Born Extremely Preterm.Dorner RA, Li L, DeMauro SB, Schmidt B, Zangeneh SZ, Vaucher Y, Wyckoff MH, Hintz S, Carlo WA, Gustafson KE, Das A, Katheria A; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.J Pediatr. 2025 Mar;278:114428. doi: 10.1016/j.jpeds.2024.114428. Epub 2024 Dec 4.PMID: 39643110Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textExtended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial.Carlo WA, Eichenwald EC, Carper BA, Bell EF, Keszler M, Patel RM, Sánchez PJ, Goldberg RN, D'Angio CT, Van Meurs KP, Hibbs AM, Ambalavanan N, Cosby SS, Newman NS, Vohr BR, Walsh MC, Das A, Ohls RK, Fuller J, Rysavy MA, Ghavam S, Brion LP, Puopolo KM, Moore R, Baack ML, Colaizy TT, Baserga M, Osman AF, Merhar SL, Poindexter BB, DeMauro SB, Kumar V, Cotten CM; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA. 2025 Jun 24;333(24):2154-2163. doi: 10.1001/jama.2025.5791.PMID: 40294395 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textLate Permissive Hypercapnia for Mechanically Ventilated Preterm Infants: A Randomized Trial.Travers CP, Gentle SJ, Shukla VV, Aban I, Yee AJ, Armstead KM, Benz RL, Laney D, Ambalavanan N, Carlo WA.Pediatr Pulmonol. 2025 Jun;60(6):e71165. doi: 10.1002/ppul.71165.PMID: 40525736 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Join us for the July edition of the Simulcast Journal Club, hosted by Vic Brazil and Ben Symon. In this episode: Interprofessional Co-debriefing, AI for scenario design and for supporting sim debriefings, and some SESAM abstracts!  Also – some upcoming conferences  Australasian Simulation Congress (Adelaide 11-14 August) https://simaust.com/australasian-simulation-congress/  VSA Translational SIMposium (Northern Health 17 October)  https://vicsim.org/component/eventbooking/vsa-event/victorian-translational-simposium  The July papers  Joyce LR, Meeks M, Somerville SG. Interprofessional co-debriefing in simulation—role modeling collaboration: a qualitative study. Simul Healthc. 2025;00(00):1–9.   Hong E, et al. Exploring the use of a large language model in simulation debriefing: an observational simulation-based pilot study. Simul Healthc. 2025;00(00):1–6.   Maaz S, et al. Prompt design and comparing large language models for healthcare simulation case scenarios. J Healthc Simul. 2025 May 12.   Selected Abstracts from the Annual Meeting of SESAM - the Society for Simulation in Europe, 2025. Adv Simul 10 (Suppl 1), 35 (2025).    Another great month on Simulcast.  Happy listening 

Send us a textNeste episódio especial, convidamos Fabiana Bacchini, brasileira que vive há mais de 20 anos no Canadá, para uma conversa profunda, emocionante e inspiradora. Mãe de um bebê que nasceu com apenas 26 semanas de gestação e enfrentou mais de 120 dias na UTI Neonatal, Fabiana compartilha como essa vivência a impulsionou para o ativismo e a defesa dos direitos das famílias na neonatologia.A partir de sua experiência como mãe de UTI, Fabiana se tornou uma incansável promotora dos modelos Family Integrated Care (FI Care) e Family Centered Care (FC Care). Hoje, ela atua como diretora executiva da Canadian Premature Babies Foundation, onde lidera iniciativas que buscam colocar as vozes e as perspectivas das famílias no centro do cuidado e da pesquisa neonatal.Neste episódio, discutimos a importância da inclusão dos pais como parceiros ativos nos cuidados, os desafios enfrentados por famílias de prematuros, e como a colaboração entre profissionais e cuidadores pode melhorar desfechos e humanizar a prática neonatal. Também exploramos o papel essencial da advocacy e da representação familiar nas pesquisas científicas, construindo pontes entre vivências reais e a produção de conhecimento.Prepare-se para uma conversa inspiradora, que nos convida a repensar práticas, escutar com mais atenção e agir com mais empatia.#PodcastNeonatal #Neonatologia #Prematuridade #FamilyCenteredCare #FamilyIntegratedCare Se você quiser conhecer a Canadian Premature Babies Foundation: https://www.cpbf-fbpc.org/researchPublicações com participação de pais: https://www.cpbf-fbpc.org/publicationsPublicações com participação da Fabiana Bacchini: https://scholar.google.com/citations?hl=en&user=cKzeiukAAAAJ Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “Use of Text-to-Image Artificial Intelligence Model in Preoperative Counseling for Lip-Lift Procedures” by Huang, Balas, Yan, and Wulc. Read the article for FREE: https://bit.ly/TexttoImageAiLip Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode of Season 6 I am joined by guest expert Heather Barnard, from Tech Healthy Families about Digital Wellness and how we can have conversations around this with our families.  You will hear us talk about: why it is important to support ourselves and our children with digital wellness how we can support ourselves and our children with digital wellness how as parents and adults we can upskill our own media literacy so we can confidently guide our children online   Find out more about Heather~ Heather help parents cut through the overwhelm of raising kids in a digital world. With 21 years of teaching experience (12 in 1:1 device schools), she knows firsthand how tricky it can be to balance screen time, social media, and online safety—without constant arguments. Website -https://www.techhealthyfamilies.com/ Instagram - https://www.instagram.com/techhealthyfamilies/   This episode of the Self Care Edit is sponsored by Juno Magazine ~ "a print and digital bi-monthly magazine which promotes a natural approach to family life and inspires and supports parents as they journey through the challenges of parenting." Find out more and get your copy or subscription here ~ https://junomagazine.com/   To see more of Emma, the Journal Club, Journals, Online Courses and Coaching Sessions, resources and workshops head to: Journals - https://www.amazon.co.uk/stores/Ms-Emma-Benyon/author/B0DMM7KKTG Facebook - @emmabenyon.coach Instagram - @emmabenyon.coach Instagram - @journalingwithemma Website - https://emmabenyoncoaching.co.uk/ Email - emma@emmabenyoncoaching.co.uk If you are ready to deepen your journaling practice, find out more about my four week online journaling course ~ https://emmabenyoncoaching.co.uk/journaling-courses/mindfulmomentsjournalingcourse Sign up to the newsletter and get your Wellness Life Check and review your life right now ~ https://dashboard.mailerlite.com/forms/851037/114640934069601722/share

In this special episode, Vic is joined by Rune Dall Jensen and Gabriel Reedy to preview the AMEE Simulation Committee journal club session. This is an annual event held each year at the AMEE (International Association for Health Professions Education) conference; this year in Barcelona Spain on 23rd – 27th August.  Rune and Gabe tell us about the event, the way papers are selected, and then preview the top 4 that will be presented at the event. For AMEE 2025 registration – link here  The papers: -  Bevis Z, Nestel D, Kumar A, Gibson S, Kavanagh M, Rosado C, et al. Instruction and guidance in healthcare simulation: a scoping review. J Healthc Simul. Published online 5 Mar 2025.  Behrens CC, Dolmans DH, Driessen EW, Gormley GJ. ‘Dancing with emotions': An interpretive descriptive study of facilitators' recognition and response to students' emotions during simulation. Med Educ. 2025;59(4):439-448.  Evans JC, Evans MB, Lingard L. Team cognition in healthcare simulation: a framework for deliberate measurement. Adv Simul (Lond). 2025;10:12. doi:10.1186/s41077-025-00333-7  Drake G, Drewek K. “I Hate Sim!”—Using psychotherapeutic concepts to help educators attend to challenging states of mind during simulation prebriefs. Simul Healthc. 2024;19(6):e147-e153.     Happy listening!  vb 

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “A Prospective Comparison of Patient-Reported Outcomes after Facial Laser Resurfacing” by Arias, Gala, Stetz, et al. Read the article for FREE: https://bit.ly/FacialLzrPROs Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode of Season 6 I am sharing some practical tips to help you start writing. Writing about my journey through motherhood and through the past few years of transformation; through poetry, blogs and articles has given me a space to reflect, explore and be creative with the rollercoaster of emotions. You will hear me talk about: why I started writing and the tools I use a poem I wrote during Covid three simple ways you can start writing   This episode of the Self Care Edit is sponsored by Juno Magazine ~ "a print and digital bi-monthly magazine which promotes a natural approach to family life and inspires and supports parents as they journey through the challenges of parenting." Find out more and get your copy or subscription here ~ https://junomagazine.com/   To see more of Emma, the Journal Club, Journals, Online Courses and Coaching Sessions, resources and workshops head to: Journals - https://www.amazon.co.uk/stores/Ms-Emma-Benyon/author/B0DMM7KKTG Facebook - @emmabenyon.coach Instagram - @emmabenyon.coach Instagram - @journalingwithemma Website - https://emmabenyoncoaching.co.uk/ Email - emma@emmabenyoncoaching.co.uk If you are ready to deepen your journaling practice, find out more about my four week online journaling course ~ https://emmabenyoncoaching.co.uk/journaling-courses/mindfulmomentsjournalingcourse Sign up to the newsletter and get your Wellness Life Check and review your life right now ~ https://dashboard.mailerlite.com/forms/851037/114640934069601722/share

For more exclusive content on metabolic health and therapy, check out our membership platform for free: https://membership.metabolicinitiative.comIn this Journal Club edition of The Metabolic Link, hosts - Victoria Field, Dr. Dominic D'Agostino, and Dr. Angela Poff dissect two powerful papers reshaping our understanding of metabolic health. First up: a striking human study showing that exposure to sugar rationing during the first 1,000 days of life reduced the risk of type 2 diabetes and hypertension decades later—offering a rare glimpse into how early-life nutrition programs lifelong health. Then, the team dives into a landmark publication proposing a clinical research framework for ketogenic metabolic therapy in glioblastoma. With insights on developmental programming, public policy, and personalized metabolic approaches to cancer, this is a must-listen for anyone passionate about where science meets societal change.Special thanks to the sponsors of this episode:✅ Genova Connect – Get 15% off any test kit with code METABOLICLINK here✅ ZocDoc - Find and instantly book a top-rated doctor here✅ Fatty15 – Get 15% off a 90-day Starter Kit with code METABOLICLINK hereRead both papers here: Exposure to sugar rationing in the first 1000 days of life protected against chronic diseaseClinical research framework proposal for ketogenic metabolic therapy in glioblastomaIn every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: Instagram Facebook YouTube LinkedIn Please keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

Send us a textEstá no ar o Episódio 58 do Podcast A Incubadora! Neste programa quinzenal, discutimos evidências científicas recentes e relevantes para a prática em neonatologia, com foco em artigos que possam informar o cuidado clínico de forma crítica, acessível e em língua portuguesa.Neste episódio, você vai ouvir a análise de quatro estudos que abordam temas centrais para o cuidado neonatal:Predicting extubation failure in preterm infants using lung ultrasound – um estudo de acurácia diagnóstica que avalia o uso do ultrassom pulmonar para prever falhas de extubação em prematuros; https://pubmed.ncbi.nlm.nih.gov/39160076/Does the evidence support in utero influences on later health and disease? – uma revisão sistemática dos artigos mais citados de Barker, questionando as bases da hipótese das origens do desenvolvimento da saúde e doença (DOHaD); https://www.nature.com/articles/s41372-024-01889-4A Clinical Monitoring Approach for Early Onset Sepsis: A Community Hospital Experience – relato de experiência sobre uma abordagem baseada em monitoramento clínico para sepse neonatal precoce; https://pubmed.ncbi.nlm.nih.gov/34935049/Extended Caffeine for Apnea in Moderately Preterm Infants (MoCHA Trial) – ensaio clínico que investiga o impacto do uso prolongado de cafeína em prematuros moderados. https://jamanetwork.com/journals/jama/article-abstract/2833418Se você é profissional da saúde neonatal e busca se manter atualizado(a) com ciência de qualidade, esse episódio é pra você. Dá o play e vem com a gente! Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Lembrando que o Podcast está no Instagram, @incubadora.podcast, onde a gente posta as figuras e tabelas de alguns artigos. Se estiver gostando do nosso Podcast, por favor dedique um pouquinho do seu tempo para deixar sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. Isso é importante para a gente poder continuar produzindo os episódios. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Lara Devgan, MD, MPH, discuss the following articles from the July 2025 issue: “Improvement in Temple Hollowing with VYC-20L Hyaluronic Acid Filler: A Multicenter Randomized Controlled Trial of Safety and Effectiveness” by Montes, Hooper, Jones, et al. Read the article for FREE: https://bit.ly/TemplHollVYC-20L Special guest, Lara Devgan, MD, MPH is an internationally known aesthetic plastic surgeon practicing aesthetic surgery of the face, breast, and body as well as facial injectables in New York City. She attended Yale for her undergraduate education followed by Johns Hopkins for medical school and the Columbia/Cornell program for plastic surgery residency. She is the founder and CEO of the medical-grade skincare line Dr. Devgan Scientific Beauty, serves as a medical expert for ABC News, is an editorial consultant for the Lancet, and lectures internationally on aesthetic plastic surgery. READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJuly25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

In this episode of Season 6 I am sharing about finding your thing in motherhood. This topic is so relevant for so many of us when we feel stuck and lost in who we are. You will hear me talk about: Why we might stay stuck Journaling prompts for finding your  thing Being accountable to bringing more joy,  more you, into your life   This episode of the Self Care Edit is sponsored by Juno Magazine ~ "a print and digital bi-monthly magazine which promotes a natural approach to family life and inspires and supports parents as they journey through the challenges of parenting." Find out more and get your copy or subscription here ~ https://junomagazine.com/   To see more of Emma, the Journal Club, Journals, Online Courses and Coaching Sessions, resources and workshops head to: Journals - https://www.amazon.co.uk/stores/Ms-Emma-Benyon/author/B0DMM7KKTG Facebook - @emmabenyon.coach Instagram - @emmabenyon.coach Instagram - @journalingwithemma Website - https://emmabenyoncoaching.co.uk/ Email - emma@emmabenyoncoaching.co.uk If you are ready to deepen your journaling practice, find out more about my four week online journaling course ~ https://emmabenyoncoaching.co.uk/journaling-courses/mindfulmomentsjournalingcourse Sign up to the newsletter and get your Wellness Life Check and review your life right now ~ https://dashboard.mailerlite.com/forms/851037/114640934069601722/share

Drs. Akshay Thomas and Sarwar Zahid join for a journal club podcast discussion of three recent high-impact articles:Visual Fields in Diabetic Retinopathy (https://www.ophthalmologyretina.org/article/S2468-6530(25)00208-8/abstract)Gender Differences in Case Volume (https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2833393)Private Equity Practices and Retinal Detachment Volume (https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2024.01204?journalCode=hlthaff)Relevant Financial Disclosures: NoneYou can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Send us a textSevere Neonatal Morbidity and All-Cause and Cause-Specific Mortality Through Infancy and Late Adolescence.Graham H, Johansson K, Persson M, Norman M, Razaz N.JAMA Pediatr. 2025 Jun 10:e251873. doi: 10.1001/jamapediatrics.2025.1873. Online ahead of print.PMID: 40493844As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textProne Positioning Was Associated With Less Hypoxemic Events and Improved Feeding Tolerance in Preterm Infants.Bohnhorst B, Lutz E, Pirr S, Peter C, Böhne C.Acta Paediatr. 2025 May 26. doi: 10.1111/apa.70153. Online ahead of print.PMID: 40418109As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textProphylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm.Baud O, Lehert P; PREMILOC study group.Eur J Pediatr. 2025 Jun 14;184(7):419. doi: 10.1007/s00431-025-06248-9.PMID: 40515786 Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textImpact of teleneonatology on time to goal temperature in outborn neonates with hypoxic-ischemic encephalopathy requiring therapeutic hypothermia.Kaczor M, Hentz R, Youssef PE, Fine A, Fang J.J Perinatol. 2025 May 29. doi: 10.1038/s41372-025-02324-y. Online ahead of print.PMID: 40442292As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textFrom Warm to Cold: Feeding Cold Milk to Preterm Infants with Uncoordinated Oral Feeding Patterns.Ferrara-Gonzalez L, Kamity R, Htun Z, Dumpa V, Islam S, Hanna N.Nutrients. 2025 Apr 26;17(9):1457. doi: 10.3390/nu17091457.PMID: 40362766 Free PMC article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textNorepinephrine versus Dopamine for Septic Shock in Neonates: A Randomized Controlled Trial.Mazhari MYA, Priyadarshi M, Singh P, Chaurasia S, Basu S.J Pediatr. 2025 Jul;282:114599. doi: 10.1016/j.jpeds.2025.114599. Epub 2025 Apr 17.PMID: 40252959 Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textAll-cause mortality and infection-related outcomes of hospital-initiated kangaroo care versus conventional neonatal care for low-birthweight infants: a systematic review and meta-analysis.Minotti C, Jost K, Aghlmandi S, Schlaeppi C, Sieswerda E, van Werkhoven CH, Schulzke SM, Bielicki JA.Lancet Child Adolesc Health. 2025 Jul;9(7):470-483. doi: 10.1016/S2352-4642(25)00130-0. Epub 2025 May 26.PMID: 40441171 Free article.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this week's Journal Club, Ben and Daphna unpack a series of recent studies exploring outcomes in neonatology—from long-term mortality after severe neonatal morbidity to short-term feeding strategies in preterm infants.They open with a large population-based Swedish study showing that infants who experience severe neonatal morbidities face elevated mortality risks well into adolescence—especially those with neurological complications. The discussion highlights how early-life diagnoses carry weight far beyond the NICU, and how long-term support systems may not be fully equipped to manage that risk.Next, the hosts examine a small German crossover trial on prone positioning, revealing that even simple changes in posture may cut hypoxemic episodes in half. They follow this with a randomized trial comparing dopamine and norepinephrine for neonatal septic shock, a data-heavy look at the nuanced physiology behind first-line interventions.The episode rounds out with studies on cold milk for feeding dysphagia, late-onset sepsis risk with hydrocortisone, the impact of tele-neonatology on cooling time in HIE, and a new meta-analysis on kangaroo care's role in reducing infection.It's a pragmatic, fast-paced overview of recent literature shaping how we care for vulnerable newborns. As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this engaging session of the Oculofacial Podcast Journal Club, hosted by Dr. Sonja Sipen, a panel of esteemed oculoplastic surgeons reviews a series of cutting-edge studies from the recent OPRS journal. These discussions span several hot topics including the management of subperiosteal abscesses, the potential effects of botulinum toxin on tear production, and innovative treatments for eyelid keloids. Each guest brings their unique perspective, shaped by their geographical practice locations and diverse patient demographics. The episode opens with Dr. Jimmy Sismanis's analysis of a study on subperiosteal abscess management. He discusses the evolution of treatment protocols and the importance of multidisciplinary approaches, especially in pediatric cases, pointing out that newer data is crucial for contemporary practice. Transitioning to aesthetics, Dr. Jordan Conger examines a compelling paper on how botulinum toxin injections for facial rejuvenation may inadvertently affect tear production. Despite the findings suggesting a statistically significant reduction in tear production, the clinical consequences remain minimal. Finally, Dr. Christina Choi delves into the efficacy of using ultrapulse CO2 laser combined with human epidermal growth factor gel for treating If you're an ASOPRS Member, Surgeon or Trainee and are interesting in hosting a podcast episode, please submit your idea by visiting: www.asoprs.memberclicks.net/podcast  

Join us for the June edition of the Simulcast Journal Club, hosted by Vic Brazil and Ben Symon. In this episode: Embedded participants in simulation, publishing study protocols, improving research study enrolment through simulation, and improving sustainability in simulation (and in healthcare. (Oh and Ben has started a Taryn Taylor fan club….)  The papers  Paguio JT, Tieu M, Davies EL. Functions and roles of embedded participants in health simulation – an exploratory qualitative observational study protocol. J Healthc Simul. 2025 Apr 28.  Walker S, Purdy E, Houghton H, Dace W, Brazil V. Navigating professional identities: nursing faculty as embedded simulation participants in medical student simulations. Adv Simul. 2025;10(28). Fatovich DM, Carey S, Iliff J, Jowitt T, Weber DG, Vance JS. Integrating research practice into resuscitation simulation training improves recruitment into complex clinical trials. Emerg Med Australas. 2025;37:e70064. Mitchell K, Canham R, Hughes K, Tallentire VR. Simulation-based education and sustainability: creating a bridge to action. Adv Simul. 2025;10(27).   Another great month on Simulcast.  Happy listening    

In this episode Dr's J and Santhosh once again perform a roundup of whats new in the medical world, this time with an emphasis on some creative engineered solutions to medical issues. Along the way they cover the plural of hiatus, 3d printing cells inside the body, shape shifting drug treatments, italian respirator innovations, snorkeling ventilators, time dosed vaccine delivery, a brief rant about rfk junior and the vaccine commision, mosquito STD's and more! so sit back, relax and learn whats new in medicine!Further Readinghttps://www.science.org/doi/10.1126/science.adt0293https://www.3dprintingmedia.network/forums/topic/charlotte-valve-by-isinnova-for-non-invasive-ventilator/https://news.mit.edu/2025/particles-carrying-multiple-vaccine-doses-could-reduce-need-follow-up-shots-0515https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202501168https://www.nature.com/articles/s41598-024-83242-5Support Us spiritually, emotionally or financially here! or on ACAST+travelmedicinepodcast.comBlueSky/Mastodon/X: @doctorjcomedy @toshyfroTikotok: DrjtoksmedicineGmail: travelmedicinepodcast@gmail.comSpotify: https://open.spotify.com/show/28uQe3cYGrTLhP6X0zyEhTPatreon: https://www.patreon.com/travelmedicinepodcast Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Award-winning PRS Journal Club Podcast, 2025 Resident Ambassadors to the PRS Editorial Board – Christopher Kalmar, Ilana Margulies, and Amanda Sergesketter- and special guest, Chris Campbell, MD, discuss the following articles from the June 2025 issue: “Superior Retention of Aged Fat Graft by Supplementing Young Adipose-Derived Stromal Cells in a Murine Model” by Tran, Jin, Zhou, et al. Read the article for FREE: https://bit.ly/StromalCellEffect Special guest, Chris Campbell, MD is the director of microsurgery and associate program director of the Plastic Surgery Residency Program at the University of Virginia. In addition to his cosmetic practice, Dr. Campbell performs complex cancer reconstruction. After completing undergraduate and medical school at the University of North Carolina, he completed plastic surgery residency at the University of Virginia and completed subspecialty training in cancer reconstruction and microsurgery at MD Anderson Cancer Center in Houston.  READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJune25Collection The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Today is our third episode in our collaborative series with BMJ Thorax. Our mission at Pulm PEEPs is to disseminate and promote pulmonary and critical care education, and we highly value the importance of peer reviewed journals in this endeavor. … Continue reading →